Prazosin vs Doxazosin: Differences in Indications

Indications Established by Guidelines

The American College of Cardiology states that both prazosin and doxazosin are approved for hypertension, but are considered second-line agents due to the increased risk of orthostatic hypotension, especially in elderly patients 1
The American College of Cardiology recommends that prazosin requires dosing 2-3 times a day (2-20 mg/day) for adequate control of blood pressure over 24 hours 1, 2
The American College of Cardiology notes that doxazosin has a pharmacokinetic advantage with once-daily dosing (1-16 mg/day), maintaining its antihypertensive effect for 24 hours 1, 2

The American Urological Association explicitly states that the data is insufficient to support the use of prazosin for HPB 2
The guidelines recommend alfuzosin, doxazosin, tamsulosin, or terazosin, which have established efficacy with improvements of 4-6 points on the AUA Symptom Index 2
The lack of rigorous clinical trial data compared to other alpha-blockers is the reason why prazosin is not recommended for HPB 2
Doxazosin may be considered as a second-line agent in patients with concomitant HPB 1, 3

The American College of Cardiology recommends prazosin for nightmares associated with TEPT with Level A evidence 2
The dosing for TEPT starts with 1 mg at bedtime, increasing 1-2 mg every few days until an effective average dose of approximately 3 mg, with some studies using average doses of 9.5-13.3 mg/day 2

Both prazosin and doxazosin are associated with orthostatic hypotension, especially in elderly patients 1, 3
The first dose of prazosin should be administered at bedtime to reduce the risk of first-dose syncope 2
Elderly patients and those on multiple medications have a higher risk of orthostatic hypotension, requiring close monitoring of blood pressure 2, 3
Avoid abrupt discontinuation of prazosin, although it does not cause withdrawal phenomena like clonidine 2, 4

Do not prescribe prazosin for HPB: the guidelines are clear that the data is insufficient; use doxazosin, terazosin, tamsulosin, or alfuzosin instead 2
Do not assume therapeutic equivalence: although structurally related, prazosin has a specific indication for TEPT that doxazosin does not have in guidelines 2
Do not ignore the risk of weight gain with doxazosin: studies have shown that doxazosin was associated with significant weight gain, probably secondary to expansion of extracellular fluid volume 5
Do not combine with other CNS depressants without caution: the combination may cause additive sedation and orthostatic hypotension 3

Crushing extended-release tablets, such as Prazopress XL, disrupts sustained-release properties, leading to rapid absorption with risk of severe hypotension and first-dose syncope, as noted by the American Academy of Sleep Medicine 6

The American Academy of Sleep Medicine suggests that switching to standard immediate-release prazosin tablets, which can be safely crushed and administered 2-3 times daily, may be a viable alternative to Prazopress XL 6

Prazosin can be safely discontinued without a prolonged taper because it does not cause the rebound hypertension, tachycardia, or hypertonia seen with centrally-acting agents like clonidine, as stated by the Mayo Clinic Proceedings 7

The American Urological Association is not cited for any relevant information in this article, however, the Mayo Clinic Proceedings states that prazosin does not require slow tapering to prevent rebound hypertension, unlike centrally-acting agents such as clonidine 7